Cowen Starts Immunomedics (IMMU) at Outperform

Cowen initiates coverage on Immunomedics (NASDAQ: IMMU) with a Outperform rating and a price target of $15.00.

Analyst Dr. Phil Nadeau comments "Immunomedics' lead candidate IMMU-132 has produced compelling Ph. II data in
the treatment of relapsed/refractory mTNBC and our physician consultants expect IMMU-132 to become part of the standard of care. We project a FY2019 launch, and that IMMU-132 will achieve $720MM in worldwide revenue in mTNBC by 2025."

FY 2017 EPS estimate is for a loss of $1.10 and FY 2018 EPS estimate is for a loss of $0.70.

For an analyst ratings summary and ratings history on Immunomedics click here. For more ratings news on Immunomedics click here.

Shares of Immunomedics closed at $7.47 yesterday.

You May Also Be Interested In

• Amazon.com (AMZN) PT Raised to $215 at UBS
• Nippon Life India Asset Management Ltd (NAM:IN) PT Raised to INR665 at HSBC
• Meta Platforms Inc. (META) PT Lowered to $575 at UBS, 'shares are offering a 3-to-1 skew'